Trials / Completed
CompletedNCT03031093
Aerosol Therapy in Obese COPD Patients.
Aerosol Therapy With High Flow Nasal Cannula (HFNC) in Obese COPD Patients. Aerosol Deposition Pattern and Predictive Values.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Universidade Federal do Rio Grande do Norte · Academic / Other
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Accepted
Summary
This study has the objective to clarify the factors that directly influence the effectiveness of inhaled drug deposition in obese patients with chronic obstructive pulmonary disease (COPD) and suggest the use of High Flow Nasal Cannula (HFNC) during their inhalation therapy.
Detailed description
This study has the objective to clarify the factors that directly influence the effectiveness of inhaled drug deposition in obese patients with chronic obstructive pulmonary disease (COPD) and then formulate specific strategies to control the evolution of this disease. The suggested strategy in order to implement the aerosol therapy is the use of High Flow Nasal Cannula (HFNC) during these patient´s inhalation therapy. It will consist in a cross-over clinical trial. The population will be composed by volunteers of both genders, aged between 45-70 years old. Four distinct groups will be formed: obese participants without copd; obese participants with copd; non obese participants without copd; non-obese participants with copd.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | inhalation protocol | technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution |
| DEVICE | High Flow Nasal Cannula | aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen. |
Timeline
- Start date
- 2017-12-02
- Primary completion
- 2018-04-03
- Completion
- 2018-05-05
- First posted
- 2017-01-25
- Last updated
- 2019-10-22
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03031093. Inclusion in this directory is not an endorsement.